Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFP-14927 in advanced solid tumors
NCT03943004Phase 1Recruiting
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Sep 2019
- Primary completion
- Mar 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DFP-14927 in solid tumor, gastroesophageal junction cancer, pancreatic cancer (PC) and 1 more, sponsored by Delta-Fly Pharma, Inc. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 1 more. Started Sep 2019; status: recruiting.
02
Drugs
DFP-14927
03
Conditions
solid tumorgastroesophageal junction cancerpancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03943004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943004.